ArticleMolecular biology reports2026
P38γ drives aerobic glycolysis in liver sinusoidal endothelial cells and regulates alcoholic liver disease via the PFKFB3 signaling pathway.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesDuring alcoholic liver disease (ALD), alcohol induces functional impairment of LSECs, thereby exacerbating inflammation and fibrosis. This research aims to investigate whether P38γ drives aerobic glycolysis in LSECs via the PFKFB3 signaling axis, thereby participating in the progression of ALD.
methodsAn ALD cell model was established by treating primary hHSECs with EtOH, followed by silencing P38γ expression. The expression of LYVE-1, CD34, HK2, PKM2, LDHA, and PFKFB3/p-PFKFB3 was assayed by Western blotting, RT-qPCR, and immunofluorescence. Cell viability and migration were evaluated via the MTT method and Transwell assay, respectively. Angiogenesis ability was analyzed through the Matrigel tube formation assay. Levels of lactate, ATP, TNF-α, IL-1β, IL-6, and TGF-β1 were measured via ELISA. Glucose uptake efficiency was assessed by the 2-NBDG uptake assay. The co-localization of LYVE-1 and CD34 was observed via immunofluorescence. PFKFB3 was overexpressed in rescue experiments to verify its role in P38γ-regulated glycolysis.
resultsEtOH induction upregulated P38γ expression in hHSECs. Silencing P38γ enhanced cell viability, promoted the expression of the LSEC differentiation marker LYVE-1, and inhibited the expression of the dedifferentiation marker CD34. Silencing P38γ suppressed EtOH-induced migration of hHSECs, abnormal angiogenesis, inflammation, and fibrosis. Silencing P38γ reduced glucose uptake, lactate production, and ATP levels in cells and downregulated HK2, PKM2, and LDHA. P38γ drove glycolysis by phosphorylating PFKFB3. Overexpression of PFKFB3 reversed the inhibitory effect on glycolysis caused by P38γ silencing.
conclusionP38γ is a key driver of hHSEC injury in ALD. P38γ reprograms cellular energy metabolism and promotes hHSEC capillarization, inflammation, and fibrosis via the P38γ/PFKFB3 signaling axis.
Indexed as
Identifiers
42201586What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.